361 Capital’s Assembly Biosciences ASMB Stock Holding History

361 Capital’s Portfolio ASMB Stock Details ASMB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-9,547	Closed	-$2.59M	–	322
2018 Q4	$2.59M	Buy	+9,547	New	+$2.76M	0.53%	29

Other funds holding ASMB

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

361 Capital's ASMB Position: Q1 2019 in Review

361 Capital sold out of Assembly Biosciences (ASMB) in Q1 2019, closing a stake of 9,547 shares — an estimated $2.59M sold.

361 Capital first reported a position in ASMB in Q4 2018 and held it in 1 quarter. The position peaked at $2.59M in Q4 2018. 103 funds tracked by Wall St. Rank hold ASMB as of Q1 2019.

361 Capital reported no remaining Assembly Biosciences position as of Q1 2019 after selling out during the quarter.
361 Capital sold 9,547 Assembly Biosciences shares in Q1 2019, an estimated $2.59M.
361 Capital first reported a position in Assembly Biosciences in Q4 2018 and held it in 1 quarter.
361 Capital's Assembly Biosciences position peaked at $2.59M in Q4 2018.
103 funds tracked by Wall St. Rank held Assembly Biosciences as of Q1 2019.

Based on 361 Capital's 13F filing for Q1 2019, filed 7 May 2019.